Management claims semiconductor assumptions are unchanged, yet widened EBITDA guidance to a range of -3% to +8%.
Thesis: Merck is a derivative play with zero leverage. They supply materials to the kings (TSMC) but hold no pricing power. The Electronics growth narrative is hitting a 'capacity ceiling' where volume grows but margin doesn't follow. The massive widening of guidance bands is a confession of low visibility disguised as prudence. Life Science recovery is a destocking mean-reversion, not a new growth cycle.
Verdict: SHORT — Conviction: MEDIUM
Catalyst: Q2 earnings when the 'phasing' of projects likely converts to explicit cancellations or further delays.
Key Risk: A rapid acceleration in NAND/Memory pricing could drive the top end of their materials guidance, squeezing the short.
The Tell: The CFO's explanation for the €400m receivables spike: it followed 'a particularly strong quarter of cash collection in Q4.' This implies they pulled forward every cent possible to dress up year-end 2024, leaving Q1 2025 exposed.
Friction Level: HIGH_FRICTION — Management claims 'phasing' of projects is the only change, while the numbers imply structural demand softening and a lack of pricing power.
Report not found
The report data is no longer available. Please return to the archive.